drugset / Trial / NCT00770900

Study to Evaluate the Inflammatory Cells Activity in Patients With Persistent Asthma Treated With Montelukast (0476-403)(COMPLETED)

NCT00770900

Phase 4 Completed 83 enrolled University of Brasilia
RandomizedParallel-groupDouble-blindTreatment

Summary

Verify if the quantitative parameters of the eosinophils activation and phagocyte system function show a predictive value for clinical response and prognostic in patients with persistent asthma treated with montelukast

Timeline

Start
2008-09
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Montelukast Other / unclassified 4 mg
Subject Montelukast Other / unclassified 5 mg
Subject Montelukast Other / unclassified 10 mg

Indications